相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Heart Disease and Stroke Statistics-2010 Update A Report From the American Heart Association
Donald Lloyd-Jones et al.
CIRCULATION (2010)
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study
Alexandre Mebazaa et al.
EUROPEAN HEART JOURNAL (2010)
The current and future management of acute heart failure syndromes
Peter S. Pang et al.
EUROPEAN HEART JOURNAL (2010)
Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia
Tomas Berl et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Effects of tolvaptan on dyspnoea relief from the EVEREST trials
Peter S. Pang et al.
EUROPEAN HEART JOURNAL (2009)
Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure
Punniyakoti T. Veeraveedu et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Efficacy and Safety of the Vasopressin V1A/V2-Receptor Antagonist Conivaptan in Acute Decompensated Heart Failure: A Dose-Ranging Pilot Study
Steven R. Goldsmith et al.
JOURNAL OF CARDIAC FAILURE (2008)
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International, Multicenter, Randomized, Placebo-Controlled Trial
James E. Udelson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, 1498 a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects
Susan E. Shoaf et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure
Punniyakoti T. Veeraveedu et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial
Mihai Gheorghiade et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial
Vic Hasselblad et al.
EUROPEAN JOURNAL OF HEART FAILURE (2007)
Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
James E. Udelson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry
Mihai Gheorghiade et al.
EUROPEAN HEART JOURNAL (2007)
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial
Marvin A. Konstam et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Tolvaptan, an orally active vasopressin V-2-receptor antagonist-pharmacology and clinical trials
Toshiki Miyazaki et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Congestion in acute heart failure syndromes: An essential target of evaluation and treatment
Mihai Gheorghiade et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
Robert W. Schrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure
Mihai Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia
M Gheorghiade et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
LC Costello-Boerrigter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Acute heart failure syndromes -: Current state and framework for future research
M Gheorghiade et al.
CIRCULATION (2005)
Vasopressin antagonism in heart failure
SR Goldsmith et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Pathophysiologic targets in the early phase of acute heart failure syndromes
M Gheorghiade et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Pharmacology of new agents for acute heart failure syndromes
M Gheorghiade et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias
SE Shoaf et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2005)
Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia
T Miyazaki et al.
ENDOCRINOLOGY (2005)
Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure - A double-blind study
S Paterna et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure -: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
L Klein et al.
CIRCULATION (2005)
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST)
M Gheorghiade et al.
JOURNAL OF CARDIAC FAILURE (2005)
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial
M Gheorghiade et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Vasopressin: A new target for the treatment of heart failure
CR Lee et al.
AMERICAN HEART JOURNAL (2003)
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure -: Results from a double-blind, randomized trial
M Gheorghiade et al.
CIRCULATION (2003)
Decompensated heart failure: Symptoms, patterns of onset, and contributing factors
GD Schiff et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Ongoing right ventricular hemodynarnics in heart failure -: Clinical value of measurements derived from an implantable monitoring system
PB Adamson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin
PR Kalra et al.
CARDIOVASCULAR RESEARCH (2001)
Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects
L Bankir
CARDIOVASCULAR RESEARCH (2001)
Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure
R Isnard et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor
Y Nakamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
分享论文
